drugset / Trial / NCT02471404

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

NCT02471404

Phase 4 Completed 939 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.

Timeline

Start
2015-09-21
Primary completion
2017-03-13
Completion
2017-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg Oral
Comparator Glimepiride Small molecule 1 mg Oral
Comparator Glimepiride Small molecule 2 mg Oral
Comparator Glimepiride Small molecule 4 mg Oral
Comparator SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral